PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: What Is Established and What Remains Uncertain for Memory Clinic Patients

What the age-40 Alzheimer's blood test shows, its limits, and what to ask at the memory clinic.

PrecivityAD2 is a blood test that helps detect brain amyloid pathology, a hallmark of Alzheimer's disease, in adults age 40 and older with cognitive symptoms. What remains uncertain is the exact cause of symptoms in any one patient, because the test aids evaluation but does not give a stand-alone Alzheimer's diagnosis. Memory clinic patients face long workups, especially at younger ages when symptoms overlap with other conditions. A blood result can help guide next steps alongside history, exams, and clinical judgment.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

Who is the test for?

The test is for adults age 40 and older who have cognitive symptoms and are undergoing evaluation for Alzheimer's disease. According to the Alzheimer's Association, the agency cleared it on Aug. 19-20, 2026 for this symptomatic group the FDA clearance announcement.

It was the third FDA-cleared Alzheimer's blood-biomarker test and the first cleared for symptomatic patients as young as 40. That age cutoff matters for younger-onset cases, which often appear between ages 40 and 64. Younger patients often wait longer for answers because memory, language, or behavior changes can mimic stress, depression, or other neurologic conditions. For them, a covered evaluation path may look like this:.

  • referral to specialized memory care for cognitive impairment
  • clinical history, cognitive testing, and medical workup
  • blood-biomarker testing to help assess amyloid likelihood
  • PET or spinal-fluid testing when needed to confirm pathology

What does the test measure?

The test measures two blood markers tied to Alzheimer's pathology. According to Practical Neurology, it uses high-resolution mass spectrometry to measure plasma Aβ42/40 ratio and percent p-tau217 the Practical Neurology report. Aβ42/40 ratio reflects amyloid processing in blood.

Percent p-tau217 reflects tau phosphorylation linked to amyloid buildup. The two results combine into an Amyloid Probability Score 2. The score groups patients as Positive, Negative, or intermediate risk for brain amyloid.

How well did it match standard tests?

In 1,142 symptomatic adults, researchers compared PrecivityAD2 with amyloid PET or cerebrospinal-fluid testing. According to C2N Diagnostics reporting, a Positive result had 97.6% positive predictive value and a Negative result had 93.1% negative predictive value the C2N test-performance summary. Positive predictive value means most Positive blood results agreed with PET or spinal-fluid evidence of amyloid.

Negative predictive value means most Negative blood results agreed with absence of amyloid on those tests. Agreement is not identity. PET and spinal-fluid tests directly assess brain or spinal-fluid pathology, while blood markers estimate likelihood and need clinical context.

What are the limits in the memory clinic?

PrecivityAD2 is not cleared for screening people without symptoms and not cleared as a stand-alone diagnosis. Results must be read with symptoms, history, and clinical assessment. The 2025 Alzheimer's Association guideline limits blood-biomarker use to cognitively impaired patients seen in specialized memory care.

High-accuracy tests can triage or substitute for PET or spinal-fluid testing in that setting, not replace clinical judgment. For practical planning, Anthem Blue Cross Blue Shield began medical-policy coverage for eligible members on Oct. 1, 2026. C2N said the FDA-cleared kit would ship later in 2026, with testing through its certified lab available in the interim.


You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.